Linked Life Data

10515191

Source:http://linkedlifedata.com/resource/pubmed/id/10515191

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10515191rdf:typepubmed:Citationlld:pubmed
pubmed-article:10515191lifeskim:mentionsumls-concept:C1257890lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0017462lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0917798lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0206529lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0205234lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C2348867lld:lifeskim
pubmed-article:10515191lifeskim:mentionsumls-concept:C0765373lld:lifeskim
pubmed-article:10515191pubmed:issue3lld:pubmed
pubmed-article:10515191pubmed:dateCreated1999-11-16lld:pubmed
pubmed-article:10515191pubmed:abstractTextThe neuroprotective effects of a selective Group II metabotropic glutamate receptor (mGluR) agonist, LY379268, have been evaluated against global and focal cerebral ischaemia. Loss of CA1 hippocampal neurones following 5 min bilateral occlusion of the carotid artery (BCAO) in the gerbil was almost completely prevented by LY379268 (10 mg/kg, i.p.) given 30 min post-occlusion (P < 0.001); 10 mg/kg 1 h after and 20 mg/kg 2 h after BCAO also produced significant neuroprotection (P < 0.05). Similarly the BCAO-induced increase in TUNEL positive cells at 5 days post-occlusion was reduced by LY379268. By contrast the size of the infarct following middle cerebral artery occlusion (MCAO) induced by endothelin-1 infusion in the rat was unaffected by either 10 or 20 mg/kg i.p. of LY379268. This contrast between the results from these two animal models with LY379268, agrees with previous data on a less potent but similarly selective mGluR2/3 agonist, LY354740. It further suggests that mGluR Group II agonists are likely to have more utility in global, than in focal, cerebral ischaemia.lld:pubmed
pubmed-article:10515191pubmed:languageenglld:pubmed
pubmed-article:10515191pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:citationSubsetIMlld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10515191pubmed:statusMEDLINElld:pubmed
pubmed-article:10515191pubmed:monthOctlld:pubmed
pubmed-article:10515191pubmed:issn0304-3940lld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:LodgeDDlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:O'NeillM JMJlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:BonoLLlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:WardM AMAlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:MonnJ AJAlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:HicksC ACAlld:pubmed
pubmed-article:10515191pubmed:authorpubmed-author:RagumoorthyNNlld:pubmed
pubmed-article:10515191pubmed:issnTypePrintlld:pubmed
pubmed-article:10515191pubmed:day8lld:pubmed
pubmed-article:10515191pubmed:volume273lld:pubmed
pubmed-article:10515191pubmed:ownerNLMlld:pubmed
pubmed-article:10515191pubmed:authorsCompleteYlld:pubmed
pubmed-article:10515191pubmed:pagination191-4lld:pubmed
pubmed-article:10515191pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:meshHeadingpubmed-meshheading:10515191...lld:pubmed
pubmed-article:10515191pubmed:year1999lld:pubmed
pubmed-article:10515191pubmed:articleTitleLY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia.lld:pubmed
pubmed-article:10515191pubmed:affiliationEli Lilly & Co., Ltd., Lilly Research Centre, Erl Wood Manor, Surrey, UK.lld:pubmed
pubmed-article:10515191pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10515191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10515191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10515191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10515191lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10515191lld:pubmed